Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CODX Stock Forecast 2026-2027
$4.29
Current Price
$15.69M
Market Cap
Buy 0
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to CODX Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
CODX Price Momentum
-23.8%
1 Week Change
+163.2%
1 Month Change
-48.2%
1 Year Change
-15.4%
Year-to-Date Change
-90.8%
From 52W High of $46.50
+240.5%
From 52W Low of $1.26
📊 TOP ANALYST CALLS
Did CODX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Co-Diagnostics is one of their latest high-conviction picks.
Latest CODX Stock Price Targets & Analyst Predictions
CODX has shown a year-to-date change of -15.4% and a 1-year change of -48.2%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for CODX. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CODX Analyst Ratings
0
Buy
1
Hold
0
Sell
CODX Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $4.29
Latest CODX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CODX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 23, 2026 | Maxim Group | Jason McCarthy | Hold | Downgrade | $N/A |
| Nov 26, 2025 | Maxim Group | Buy | Initiates | $N/A | |
| Nov 24, 2025 | HC Wainwright & Co. | Neutral | Reiterates | $N/A | |
| Oct 28, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Oct 16, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Sep 19, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Sep 17, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Aug 15, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Apr 28, 2025 | D. Boral Capital | Buy | Initiates | $N/A | |
| Mar 28, 2025 | HC Wainwright & Co. | Neutral | Maintains | $N/A | |
| Nov 11, 2024 | HC Wainwright & Co. | Neutral | Reiterates | $N/A | |
| Aug 12, 2024 | HC Wainwright & Co. | Neutral | Maintains | $N/A | |
| Jun 17, 2024 | HC Wainwright & Co. | Neutral | Reiterates | $N/A | |
| May 13, 2024 | HC Wainwright & Co. | Neutral | Maintains | $N/A | |
| Mar 15, 2024 | HC Wainwright & Co. | Neutral | Maintains | $N/A | |
| Dec 29, 2023 | HC Wainwright & Co. | Neutral | Reiterates | $N/A | |
| Nov 13, 2023 | HC Wainwright & Co. | Neutral | Maintains | $N/A | |
| Aug 14, 2023 | HC Wainwright & Co. | Neutral | Maintains | $N/A | |
| May 15, 2023 | HC Wainwright & Co. | Neutral | Reiterates | $N/A | |
| Mar 20, 2023 | HC Wainwright & Co. | Neutral | Downgrade | $N/A |
Co-Diagnostics Inc. (CODX) Competitors
The following stocks are similar to Co-Diagnostics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Co-Diagnostics Inc. (CODX) Financial Data
Co-Diagnostics Inc. has a market capitalization of $15.69M with a P/E ratio of -0.1x. The company generates $718,166 in trailing twelve-month revenue with a 64.3% profit margin.
Revenue growth is +190.3% quarter-over-quarter, while maintaining an operating margin of -6,309.1% and return on equity of -151.7%.
Valuation Metrics
Market Cap
$15.69M
Enterprise Value
$11.38M
P/E Ratio
-0.1x
PEG Ratio
0.0x
Price/Sales
23.9x
Growth & Margins
Revenue Growth (YoY)
+190.3%
Gross Margin
-32.8%
Operating Margin
-6,309.1%
Net Margin
+64.3%
EPS Growth
+190.3%
Financial Health
Cash/Price Ratio
+53.3%
Current Ratio
2.3x
Debt/Equity
12.7x
ROE
-151.7%
ROA
-52.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Co-Diagnostics Inc. (CODX) Business Model
About Co-Diagnostics Inc.
What They Do
Develops molecular diagnostic reagents and tests.
Business Model
Co-Diagnostics Inc. generates revenue by developing, manufacturing, and selling reagents and tools for diagnostic tests that utilize nucleic acid detection, primarily through its proprietary Co-Dx PCR platform. This platform supports a range of diagnostic applications, including infectious disease testing and liquid biopsy tools for cancer screening, targeting both healthcare and agricultural markets.
Additional Information
Founded in 2013 and based in Salt Lake City, Utah, Co-Diagnostics Inc. operates both domestically and internationally, with a focus on point-of-care and at-home testing solutions. The company also engages in a joint venture in India to enhance decentralized PCR testing capabilities, thereby expanding its reach and impact in the molecular diagnostics field.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
132
CEO
Mr. Dwight H. Egan
Country
United States
IPO Year
2017
Website
co-dx.comCo-Diagnostics Inc. (CODX) Latest News & Analysis
Latest News
Quick Summary
Co-Diagnostics, Inc. has signed an exclusive distribution agreement in Mexico for its Co-Dx™ PCR Pro® platform, aiming to expand its molecular diagnostics presence in Latin America.
Why It Matters
The exclusive distribution agreement in Mexico enhances Co-Diagnostics' market presence in Latin America, indicating potential revenue growth and increased demand for its PCR products.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Co-Diagnostics, Inc. announced advancements in its Ebola PCR development program through a joint venture with CoSara Diagnostics, enhancing its point-of-care testing capabilities.
Why It Matters
Co-Diagnostics' advancement in Ebola testing enhances its product offerings and market position, potentially driving revenue growth and investor confidence amid rising health concerns.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
The WHO declared a Public Health Emergency of International Concern for the Bundibugyo virus Ebola outbreak on May 17, 2026, signaling a significant shift in the biodefense landscape.
Why It Matters
The WHO's PHEIC declaration signals increased funding and focus on biodefense, potentially boosting investments in related biotech and pharmaceutical sectors.
Source: MarketBeat
Market Sentiment:
Neutral
Quick Summary
Co-Diagnostics, Inc. is advancing PCR assay development for the Bundibugyo virus amid an Ebola outbreak in DRC and Uganda, in collaboration with CoSara Diagnostics.
Why It Matters
The development of a PCR assay for the Bundibugyo virus signals potential revenue growth for Co-Diagnostics amid rising global health concerns, influencing investor sentiment and stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Co-Diagnostics, Inc. has completed the assay development for the Bundibugyo virus amid the Ebola outbreak in the DRC and Uganda, positioning itself to quickly provide testing if needed.
Why It Matters
Co-Diagnostics' progress in developing diagnostics for Ebola enhances its market position and readiness for emerging health threats, potentially boosting investor confidence and stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Co-Diagnostics Announces $3.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
25 days ago
Quick Summary
Co-Diagnostics, Inc. has entered a securities purchase agreement to sell 1,647,447 shares and warrants for 3,294,894 shares at $1.821 each in a private placement.
Why It Matters
Co-Diagnostics is raising capital through a private placement, which may dilute existing shares but also provides funds for growth, impacting share value and investor sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About CODX Stock
What is Co-Diagnostics Inc.'s (CODX) stock forecast for 2026?
Analyst forecasts for Co-Diagnostics Inc. (CODX) are not currently available. The stock is trading at $4.29.
Is CODX stock a good investment in 2026?
According to current analyst ratings, CODX has 0 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $4.29. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CODX stock?
Price predictions from Wall Street analysts for CODX are not currently available. The stock is trading at $4.29.
What is Co-Diagnostics Inc.'s business model?
Co-Diagnostics Inc. generates revenue by developing, manufacturing, and selling reagents and tools for diagnostic tests that utilize nucleic acid detection, primarily through its proprietary Co-Dx PCR platform. This platform supports a range of diagnostic applications, including infectious disease testing and liquid biopsy tools for cancer screening, targeting both healthcare and agricultural markets.
What is the highest forecasted price for CODX Co-Diagnostics Inc.?
Price targets from Wall Street analysts for CODX are not currently available. The stock is trading at $4.29.
What is the lowest forecasted price for CODX Co-Diagnostics Inc.?
Price targets from Wall Street analysts for CODX are not currently available. The stock is trading at $4.29.
What is the overall CODX consensus from analysts for Co-Diagnostics Inc.?
The overall analyst consensus for CODX is neutral. Out of 2 Wall Street analysts, 0 rate it as Buy, 1 as Hold, and 0 as Sell.
How accurate are CODX stock price projections?
Stock price projections, including those for Co-Diagnostics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 13, 2026 5:23 PM UTC